ACHF.F Stock Overview Engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Arch Biopartners Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Arch Biopartners Historical stock prices Current Share Price US$1.34 52 Week High US$1.88 52 Week Low US$0.89 Beta 1.4 1 Month Change 1.52% 3 Month Change -0.74% 1 Year Change 20.61% 3 Year Change -53.31% 5 Year Change 82.94% Change since IPO 88.73%
Recent News & Updates
Arch Biopartners Inc. Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) Jan 08
Arch Biopartners Inc. Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury Nov 12 Arch Biopartners Inc. announced that it has received CAD 0.450001 million in funding Oct 16
Arch Biopartners Inc. Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury Sep 11
Arch Biopartners Inc. Announces its Cilastatin Drug Candidate to Participate in Pontiac Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins Aug 02 Arch Biopartners Inc. announced that it has received CAD 0.6 million in funding Jul 31
See more updates
Arch Biopartners Inc. Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) Jan 08
Arch Biopartners Inc. Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury Nov 12 Arch Biopartners Inc. announced that it has received CAD 0.450001 million in funding Oct 16
Arch Biopartners Inc. Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury Sep 11
Arch Biopartners Inc. Announces its Cilastatin Drug Candidate to Participate in Pontiac Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins Aug 02 Arch Biopartners Inc. announced that it has received CAD 0.6 million in funding Jul 31
Arch Biopartners Inc. announced that it expects to receive CAD 0.6 million in funding Jul 30
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) Jun 18
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury Apr 16
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury Apr 05
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2 Mar 20
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury Mar 16
Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury Mar 08 Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial
Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024 Jan 19
Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury Jan 11
Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide Dec 22
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide Dec 13
Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide Sep 23
Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023 Jan 20
Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate Aug 06
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok) Feb 15
Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial Dec 03
Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide Aug 06
Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation Jun 11
Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19 May 05
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide Mar 17 Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide Feb 03
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc Jan 06
Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding Dec 30
Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding Dec 24
Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19 Nov 06
Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19 Oct 18
Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Oct 08 Shareholder Returns ACHF.F US Life Sciences US Market 7D -2.9% 0.9% -2.1% 1Y 20.6% -0.7% 21.3%
See full shareholder returns
Return vs Market: ACHF.F matched the US Market which returned 21.3% over the past year.
Price Volatility Is ACHF.F's price volatile compared to industry and market? ACHF.F volatility ACHF.F Average Weekly Movement 7.4% Life Sciences Industry Average Movement 9.3% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: ACHF.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACHF.F's weekly volatility (7%) has been stable over the past year.
About the Company Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals.
Show more Arch Biopartners Inc. Fundamentals Summary How do Arch Biopartners's earnings and revenue compare to its market cap? ACHF.F fundamental statistics Market cap US$86.91m Earnings (TTM ) -US$1.78m Revenue (TTM ) US$958.94k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ACHF.F income statement (TTM ) Revenue CA$1.38m Cost of Revenue CA$1.56m Gross Profit -CA$173.36k Other Expenses CA$2.40m Earnings -CA$2.57m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.04 Gross Margin -12.53% Net Profit Margin -185.89% Debt/Equity Ratio -81.2%
How did ACHF.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/12 10:52 End of Day Share Price 2025/01/10 00:00 Earnings 2024/06/30 Annual Earnings 2023/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Arch Biopartners Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Chelsea Stellick iA Capital Markets Rahul Sarugaser Raymond James Ltd.
Show 0 more analysts 
